Company news
Silo Pharma, Inc. news in 2026
Silo Pharma, Inc.'s news releases, calls and decks from 2026, newest first.
Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
September 30, 2026
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
September 18, 2026
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
September 9, 2026
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
August 18, 2026
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
August 10, 2026
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
August 6, 2026
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
July 20, 2026
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
July 13, 2026
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 9, 2026
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
July 6, 2026
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
June 29, 2026
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
June 22, 2026
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 18, 2026
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
May 6, 2026
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
April 29, 2026
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
April 28, 2026
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
April 21, 2026
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
April 19, 2026
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
April 5, 2026
Silo Pharma Announces Share Buyback Program
February 22, 2026
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
February 17, 2026
Decks in 2026
- Investor Presentation (March 2026)
Investor deck · 18 slides · March 2026